Global X China Biotech ETF (02820.HK) Rises 2.23%, AUM Reaches HKD 684 Million
Newtimespace News: As of 10:37 on August 11, Global X China Biotech ETF (02820.HK) stood at HKD 77.120, up 2.23%. The ETF opened at HKD 77.860, with the latest net asset value (NAV) at HKD 74.341, a premium of 0.24%, a 52-week high of HKD 84.500, a 52-week low of HKD 56.700, a turnover of approximately HKD 1.2695 million, and assets under management of approximately HKD 684 million.
Global X China Biotech ETF (02820.HK) closely tracks the Solactive China Biotech Index (Net Total Return). The manager of the fund is Mirae Asset Global Investments (Hong Kong) Limited. The Sub-Fund seeks to provide investment returns closely correlated with the performance of the Solactive China Biotech Index (Net Total Return) (the "Related Index") before deduction of fees and expenses.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Global X China Biotech ETF (02820.HK) Rises 1.80% in Morning Trade, Turnover Reaches HKD 1.4539 Million
- HK shares ETFs Daily Report: China biopharma breaks out across the board! Hang Seng biotech rises over 5%, Vietnam and fintech under pressure- 20260807
- Global X China Biotech ETF (02820.HK) Rises 6.19%, NAV at HKD 69.980
- Global X China Biotech ETF (02820.HK) Rises 4.42%, Turnover Reaches HKD 2.7748 Million
- Global X China Biotech ETF (02820.HK) Rises 2.65% in Morning Trade, Turnover Reaches HKD 1.6911 Million